Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

In October 2024, Novartis announced that based on its review of 48-week data from the Phase 3 MANIFEST-2 study, longer follow-up time is needed to determine the regulatory path for pelabresib in ...

(RTTNews) - Ocugen, Inc. (OCGN) Monday said that the European Medicines Agency's (EMA) Committee for Advanced Therapies (CAT) has provided a positive opinion for Advanced Therapy Medicinal Product ...

Special attention was drawn to the production of capers by Raushan Sharafatdinova, a doctoral student in agriculture - her product consists of pickled caper plant buds, which have both culinary and ...